Squarepoint Ops LLC Has $404,000 Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Squarepoint Ops LLC decreased its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 66.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,456 shares of the company’s stock after selling 92,203 shares during the period. Squarepoint Ops LLC owned 0.09% of EyePoint Pharmaceuticals worth $404,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of EyePoint Pharmaceuticals by 17.8% during the first quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock worth $49,530,000 after acquiring an additional 362,168 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of EyePoint Pharmaceuticals during the first quarter worth about $19,401,000. Fiera Capital Corp raised its position in EyePoint Pharmaceuticals by 0.9% in the 2nd quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock valued at $5,890,000 after buying an additional 5,920 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in EyePoint Pharmaceuticals by 842.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 476,250 shares of the company’s stock valued at $4,143,000 after acquiring an additional 425,717 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of EyePoint Pharmaceuticals by 32.6% in the second quarter. Bank of New York Mellon Corp now owns 204,892 shares of the company’s stock worth $1,783,000 after purchasing an additional 50,388 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Price Performance

Shares of EYPT stock opened at $8.24 on Friday. EyePoint Pharmaceuticals, Inc. has a one year low of $5.67 and a one year high of $30.99. The firm has a 50-day moving average of $8.50 and a 200-day moving average of $11.47. The company has a market cap of $429.17 million, a P/E ratio of -4.53 and a beta of 1.57.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.03). The business had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $11.61 million. EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. As a group, research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on EYPT shares. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 27th. Jefferies Financial Group began coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 20th. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, June 28th. Finally, JPMorgan Chase & Co. lowered their target price on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.57.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.